Gender-specific features of plasmatic and circulating cell alterations as risk factors in cardiovascular disease

Fundamental and Clinical Pharmacology

Volumn 24, Issue 6, 2010, Pages 665-674

  Straface, Elisabetta ^a,b   Lista, Pasquale ^a,c   Gambardella, Lucrezia ^a   Franconi, Flavia ^d   Malorni, Walter ^a,e  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^b IRCCS SAN RAFFAELE PISANA   (Italy)

^c REFERRAL CANCER CENTER OF BASILICATA   (Italy)

^d UNIVERSITY OF SASSARI   (Italy)

^e Center of Integrated Metabolomics   (Italy)

Author keywords

Cardiovascular disease; Gender; Markers; Risk factors

Indexed keywords

CARDIOVASCULAR DISEASE; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DYSLIPIDEMIA; ENDOTHELIAL DYSFUNCTION; HUMAN; HYPERTENSION; IMMOBILIZATION; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SEX DIFFERENCE; SMOKING;

BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; FEMALE; HUMANS; MALE; RISK ASSESSMENT; RISK FACTORS; SEX DISTRIBUTION; SEX FACTORS;

EID: 78349292284     PISSN: 07673981     EISSN: 14728206     Source Type: Journal    
DOI: 10.1111/j.1472-8206.2010.00860.x     Document Type: Review

References (82)

1. Ingelsson E., Pencina M.J., Tofler G.H. et al. Multimarker approach to evaluate the incidence of the metabolic syndrome and longitudinal changes in metabolic risk factors: the Framingham Offspring Study. Circulation (2007) 28 984-992.
2. Gruber C.J., Tschugguel W., Schneeberger C., Huber J.C. Production and actions of estrogens. N. Engl. J. Med. (2002) 346 340-352.
3. Vitale C., Miceli M., Rosano G.M. Gender-specific characteristics of atherosclerosis in menopausal women: risk factors, clinical course and strategies for prevention. Climacteric (2007) 2 16-20.
4. Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin. Pharmacol. Ther. (2001) 69 89-95.
5. Ridker P.M. Inflammatory biomarkers and risks of myocardial infarction, stroke, diabetes, and total mortality: implications for longevity. Nutr. Rev. (2007) 65 253-259.
6. Thayer J.F., Yamamoto S.S., Brosschot J.F. The relationship of autonomic imbalance, heart rate variability and cardiovascular disease risk factors. Int. J. Cardiol. (2010) 35 56-66.
7. Messerli F., White W.B., Staessen J.A. If only cardiologists did properly measure blood pressure: blood pressure recordings in daily practice and clinical trials. J. Am. Coll. Cardiol. (2002) 40 2201-2203.
8. Sjöberg L., Kaaja R., Tuomilehto J. Epidemiology of postmenopausal hypertension. Int. J. Clin. Pract. Suppl. (2004) 139 4-12.
9. Forouhi N.G., Sattar N., McKeigue P.M. Relation of C-reactive protein to body fat distribution and features of the metabolic syndrome in Europeans and South Asians. Int. J. Obes. Relat. Metab. Disord. (2001) 25 1327-1331.
10. Ding E.L., Song Y., Malik V.S., Liu S. Sex differences of endogenous sex hormones and risk of type 2 diabetes: a systematic review and meta-analysis. JAMA (2006) 295 1288-1299.
11. Löbner K., Knopff A., Baumgarten A. et al. Predictors of postpartum diabetes in women with gestational diabetes mellitus. Diabetes (2006) 55 792-797.
12. Hasdai D., Haim M., Behar S., Boyko V., Battler A. Acute coronary syndromes in patients with prior cerebrovascular events: lessons from the Euro-Heart Survey of Acute Coronary Syndromes. Am. Heart J. (2003) 146 832-838.
13. EUROASPIRE I and II Group; European Action on Secondary Prevention by Intervention to Reduce Events. Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries. EUROASPIRE I and II Group. European Action on Secondary Prevention by Intervention to Reduce Events. Lancet (2001) 357 995-1001.
14. Kanaya A.M., Grady D., Barrett-Connor E. Explaining the sex difference in coronary heart disease mortality among patients with type 2 diabetes mellitus: a meta-analysis. Arch. Intern. Med. (2002) 162 1737-1745.
15. Hu G., Tuomilehto J., Silventoinen K., Barengo N., Jousilahti P. Joint effects of physical activity, body mass index, waist circumference and waist-to-hip ratio with the risk of cardiovascular disease among middle-aged Finnish men and women. Eur. Heart J. (2004) 25 2212-2219.
16. Jónsdóttir L.S., Sigfússon N., Gudnason V., Sigvaldason H., Thorgeirsson G. Do lipids, blood pressure, diabetes, and smoking confer equal risk of myocardial infarction in women as in men? The Reykjavik Study J. Cardiovasc. Risk (2002) 9 67-76.
17. De Aloysio D., Gambacciani M., Meschia M. et al. The effect of menopause on blood lipid and lipoprotein levels. The Icarus Study Group. Atherosclerosis (1999) 147 147-153.
18. Jensen O.K., Nielsen F.F. The influence of sex and pre-traumatic headache on the incidence and severity of headache after head injury. Cephalalgia (1990) 10 285-293.
19. Assmann G., Schulte H. Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience). Prospective Cardiovascular Münster study. Am. J. Cardiol. (1992) 70 733-737.
20. He J., Ogden L.G., Bazzano L.A., Vupputuri S., Loria C., Whelton P.K. Risk factors for congestive heart failure in US men and women: NHANES I epidemiologic follow-up study arch. Intern. Med. (2001) 161 996-1002.
21. Barnoya J., Glantz S.A. Cardiovascular effects of secondhand smoke: nearly as large as smoking. Circulation (2005) 111 2684-2698.
22. Heiss C., Amabile N., Lee A.C. et al. Brief secondhand smoke exposure depresses endothelial progenitor cells activity and endothelial function. J. Am. Coll. Cardiol. (2008) 51 1760-1771.
23. Rångemark C., Wennmalm A. Endothelium-dependent and -independent vasodilation and reactive hyperemia in healthy smokers. J. Cardiovasc. Pharmacol. (1992) 20 198-201.
24. Dotevall A., Rångemark C., Eriksson E., Kutti J., Wadenvik H., Wennmalm A. Cigarette smoking increases thromboxane A2 formation without affecting platelet survival in young healthy females. Thromb. Haemost. (1992) 68 583-588.
25. Prasad D.S., Das B.C. Physical inactivity: a cardiovascular risk factor. Indian J. Med. Sci. (2009) 63 33-42.
26. Glass C.K., Witztum J.L. Atherosclerosis. The road ahead. Cell (2001) 104 503-516.
27. Packard R.R., Libby P. Inflammation in atherosclerosis: from vascular biology to biomarker discovery and risk prediction. Clin. Chem. (2008) 54 24-38.
28. Danesh J., Wheeler J.G., Hirschfield G.M. et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N. Engl. J. Med. (2004) 350 1387-1397.
29. Rossi E., Biasucci L.M., Citterio F. et al. Risk of myocardial infarction and angina in patients with severe peripheral vascular disease. Predictive role of C-reactive protein. Circulation (2002) 105 800-803.
30. Zebrack J.S., Muhlestein J.B., Horne B.D., Anderson J.L., Intermountain Heart Collaboration Study Group. C-reactive protein and angiographic coronary artery disease: independent and additive predictors of risk in subjects with angina. J. Am. Coll. Cardiol. (2002) 39, 632-637.
31. Verma S., Wang C.H., Li S.H. et al. A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis. Circulation (2002) 106 913-919.
32. Hutchinson D., Moots R.J. Late onset Raynaud's phenomenon, hypertension, deteriorating renal function, and a fit in a middle aged woman. Postgrad. Med. J. (2001) 77 10.
33. Yamada S., Gotoh T., Nakashima Y. et al. Distribution of serum C-reactive protein and its association with atherosclerotic risk factors in a Japanese population: Jichi Medical School Cohort Study. Am. J. Epidemiol. (2001) 153 1183-1190.
34. Saltevo J., Kautiainen H., Vanhala M. Gender differences in adiponectin and low-grade inflammation among individuals with normal glucose tolerance, prediabetes, and type 2 diabetes. Gend. Med. (2009) 6 463-470.
35. André P., Nannizzi-Alaimo L., Prasad S.K., Phillips D.R. Platelet-derived CD40L: the switch-hitting player of cardiovascular disease. Circulation (2002) 106 896-899.
36. Blake G.J., Ridker P.M. C-reactive protein and other inflammatory risk markers in acute coronary syndromes. J. Am. Coll. Cardiol. (2003) 41 37-42.
37. Heeschen C., Dimmeler S., Hamm C.W. et al. Soluble CD40 ligand in acute coronary syndromes. N. Engl. J. Med. (2003) 348 1104-1111.
38. Varo N., De Lemos J.A., Libby P. et al. Soluble CD40L: risk prediction after acute coronary syndromes. Circulation (2003) 108 1049-1052.
39. Schönbeck U., Varo N., Libby P., Buring J., Ridker P.M. Soluble CD40L and cardiovascular risk in women. Circulation (2001) 104 2266-2268.
40. Garlichs C.D., John S., Schmeisser A. et al. Upregulation of CD40 and CD40 ligand (CD154) in patients with moderate hypercholesterolemia. Circulation (2001) 104 2395-2400.
41. Varo N., Vicent D., Libby P. et al. Elevated plasma levels of the atherogenic mediator soluble CD40 ligand in diabetic patients: a novel target of thiazolidinediones. Circulation (2003) 107 2664-2669.
42. Shantha G.P., Kumar A.A., Bharadhi M.K., Arthur P. Role of gender in the associations of microalbuminuria with inflammatory markers in hypertensive subjects: a cross-sectional study. Kidney Blood Press. Res. (2009) 32 434-439.
43. Gerdes N., Sukhova G.K., Libby P., Reynolds R.S., Young J.L., Schönbeck U. Expression of interleukin (IL)-18 and functional IL-18 receptor on human vascular endothelial cells, smooth muscle cells, and macrophages: implications for atherogenesis. J. Exp. Med. (2002) 195 245-257.
44. Blankenberg S., Tiret L., Bickel C. et al. Interleukin-18 is a strong predictor of cardiovascular death in stable and unstable angina. Circulation (2002) 106 24-30.
45. Whitman S.C., Ravisankar P., Daugherty A. Interleukin-18 enhances atherosclerosis in apolipoprotein E(-/-) mice through release of interferon. Circ. Res. (2002) 90 34-38.
46. Szmitko P.E., Wang C.H., Weisel R.D., De Almeida J.R., Anderson T.J., Verma S. New markers of inflammation and endothelial cell activation: part I. Circulation (2003) 108 1917-1923.
47. Samnegård A., Hulthe J., Silveira A., Ericsson C.G., Hamsten A., Eriksson P. Gender specific associations between matrix metalloproteinases and inflammatory markers in post myocardial infarction patients. Atherosclerosis (2009) 202 550-556.
48. De Lemos J.A., Morrow D.A., Sabatine M.S. et al. Association between plasma levels of monocyte chemoattractant protein-1 and long-term clinical outcomes in patients with acute coronary syndromes. Circulation (2003) 107 690-695.
49. Gerszten R.E., Mach F., Sauty A., Rosenzweig A., Luster A.D. Chemokines, leukocytes, and atherosclerosis. J. Lab. Clin. Med. (2000) 136 87-92.
50. Shin W.S., Szuba A., Rockson S.G. The role of chemokines in human cardiovascular pathology: enhanced biological insights. Atherosclerosis (2002) 160 91-102.
51. Mosesson M.W. Fibrinogen and fibrin structure and functions. J. Thromb. Haemost. (2005) 3 1894-1904.
52. Vorster H.H. The emergence of cardiovascular disease during urbanisation of Africans. Public Health Nutr. (2002) 5 239-243.
53. Balciunas M., Bagdonaite L., Samalavicius R., Baublys A. Markers of endothelial dysfunction after cardiac surgery: soluble forms of vascular-1 and intercellular-1 adhesion molecules. Medicina (Kaunas) (2009) 45 434-439.
54. Kitamoto S., Egashira K. Endothelial dysfunction and coronary atherosclerosis. Curr. Drug Targets Cardiovasc. Haematol. Disord. (2004) 4 13-22.
55. Rotstein R., Landau T., Twig A. et al. The erythrocyte adhesiveness/aggregation test (EAAT). A new biomarker to reveal the presence of low grade subclinical smoldering inflammation in individuals with atherosclerotic risk factors. Atherosclerosis (2002) 165 343-351.
56. Zennadi R., Hines P.C., De Castro L.M., Cartron J.P., Parise L.V., Telen M.J. Epinephrine acts through erythroid signaling pathways to activate sickle cell adhesion to endothelium via LW-alphavbeta3 interactions. Blood (2004) 104 3774-3781.
57. Minetti M., Agati L., Malorni W. The microenvironment can shift erythrocytes from a friendly to a harmful behavior: pathogenetic implications for vascular diseases. Cardiovasc. Res. (2007) 75 21-28.
58. Gearing A.J., Newman W. Circulating adhesion molecules in disease. Immunol. Today (1993) 14 506-512.
59. Jenny N.S., Arnold A.M., Kuller L.H. et al. Soluble intracellular adhesion molecule-1 is associated with cardiovascular disease risk and mortality in older adults. J. Thromb. Haemost. (2006) 4 107-113.
60. Narizhneva N.V., Razorenova O.V., Podrez E.A. et al. Thrombospondin-1 up-regulates expression of cell adhesion molecules and promotes monocyte binding to endothelium. FASEB J. (2005) 19 1158-1160.
61. Nomura M. Portable glucose measuring device. Nippon Rinsho (2002) 60 565-570.
62. Straface E., Gambardella L., Canali E. et al. P-Selectin as a new gender associated biomarker in patients with metabolic syndrome. Int. J. Cardiol. (2010) [Epub ahead of print].
63. Böger R.H. Asymmetric dimethylarginine (ADMA) modulates endothelial function--therapeutic implications. Vasc. Med. (2003) 8 149-151.
64. Szuba A., Podgórski M. Asymmetric dimethylarginine (ADMA) a novel cardiovascular risk factor - evidence from epidemiological and prospective clinical trials. Pharmacol Rep. (2006) 58 16-20.
65. Chan J.R., Böger R.H., Bode-Böger S.M. et al. Asymmetric dimethylarginine increases mononuclear cell adhesiveness in hypercholesterolemic humans. Arterioscler. Thromb. Vasc. Biol. (2000) 20 1040-1046.
66. Schulze F., Maas R., Freese R., Schwedhelm E., Silberhorn E., Böger R.H. Determination of a reference value for N(G), N(G)-dimethyl-L-arginine in 500 subjects. Eur. J. Clin. Invest. (2005) 35 622-626.
67. Nishi K., Itabe H., Uno M. et al. Oxidized LDL in carotid plaques and plasma associates with plaque instability. Arterioscler. Thromb. Vasc. Biol. (2002) 22 1649-1654.
68. Yamashita H., Ehara S., Yoshiyama M. et al. Elevated plasma levels of oxidized low-density lipoprotein relate to the presence of angiographically detected complex and thrombotic coronary artery lesion morphology in patients with unstable angina. Circ. J. (2007) 71 681-687.
69. Yoshida N., Manabe H., Terasawa Y. et al. Inhibitory effects of vitamin E on endothelial-dependent adhesive interactions with leukocytes induced by oxidized low density lipoprotein. Biofactors (2000) 13 279-288.
70. Li D., Mehta J.L. Antisense to LOX-1 inhibits oxidized LDL-mediated upregulation of monocyte chemoattractant protein-1 and monocyte adhesion to human coronary artery endothelial cells. Circulation (2000) 101 2889-2895.
71. Rietzschel E.R., Langlois M., De Buyzere M.L. et al. Oxidized low-density lipoprotein cholesterol is associated with decreases in cardiac function independent of vascular alterations. Hypertension (2008) 52 535-541.
72. Van Tits L.J., Van Heerde W.L., Van Der Vleuten G.M. et al. Plasma annexin A5 level relates inversely to the severity of coronary stenosis. Biochem. Biophys. Res. Commun. (2007) 356 674-680.
73. Holvoet P., Harris T.B., Tracy R.P. et al. Association of high coronary heart disease risk status with circulating oxidized LDL in the well-functioning elderly: findings from the Health, Aging, and Body Composition study. Arterioscler. Thromb. Vasc. Biol. (2003) 23 1444-1448.
74. Densmore J.C., Signorino P.R., Ou J. et al. Endothelium-derived microparticles induce endothelial dysfunction and acute lung injury. Shock (2006) 26 464-471.
75. Chironi G.N., Boulanger C.M., Simon A., Dignat-George F., Freyssinet J.M., Tedgui A. Endothelial microparticles in diseases. Cell Tissue Res. (2009) 335 143-151.
76. Ang D.S., Kong C.F., Kao M.P., Struthers A.D. Serial bedside B-type natriuretic peptide strongly predicts prognosis in acute coronary syndrome independent of echocardiographic abnormalities. Am. Heart J. (2009) 158 133-140.
77. Munagala V.K., Burnett J.C. Jr, Redfield M.M. The natriuretic peptides in cardiovascular medicine. Curr. Probl. Cardiol. (2004) 29 707-769.
78. Casals G., Ros J., Sionis A., Davidson M.M., Morales-Ruiz M., Jiménez W. Hypoxia induces B-type natriuretic peptide release in cell lines derived from human cardiomyocytes. Am. J. Physiol. Heart Circ. Physiol. (2009) 297 550-555.
79. Levin E.R., Gardner D.G., Samson W.K. Natriuretic peptides. N. Engl. J. Med. (1998) 339 321-328.
80. Redfield M.M., Rodeheffer R.J., Jacobsen S.J., Mahoney D.W., Bailey K.R., Burnett J.C. Jr Plasma brain natriuretic peptide concentration: impact of age and gender. J. Am. Coll. Cardiol. (2002) 40 976-982.
81. Wang T.J., Nam B.H., Wilson P.W. et al. Association of C-reactive protein with carotid atherosclerosis in men and women: the Framingham Heart Study. Arterioscler. Thromb. Vasc. Biol. (2002) 22 1662-1667.
82. Coppola A., De Paola G., Suppa M. et al. Therapy optimization of heart failure through the evaluation of the plasma concentration variation of B-type natriuretic peptide. Clin. Ter. (2006) 157 495-505.